Editorial: Diabetic kidney disease: Act now or pay later

Kidney International

Volumn 77, Issue 5, 2010, Pages 375-377

  Atkins, Robert C ^a   Zimmet, Paul ^b  

^a International Society of Nephrology   (Australia)

^b International Diabetes Federation ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; EDITORIAL; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; HEALTH; HEALTH PROMOTION; HUMAN;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEALTH PROMOTION; HUMANS; WORLD HEALTH;

EID: 76749103329     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.509     Document Type: Editorial

References (28)

1. Diabetes and kidney disease: time to act. International Diabetes Federation and International Society of Nephrology: Brussels, Belgium, 2003.
2. Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
3. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
4. Yoon K, Lee JH, Kim JW et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688.
5. rd edn. International Diabetes Federation: Brussels, 2006, pp 15-109.
6. nd edn. John Wiley & Sons: Chichester, 2008, pp 499-518
7. International comparisons. In: United States Renal Data System. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, Maryland, USA, 2007, pp 239-254.
8. Appendix II. In: McDonald S, Excell L, Livingston B (eds). ANZDATA Registry Report 2008. Australia and New Zealand Dialysis and Transplant Registry: Adelaide, 2008, pp 1-97.
9. Yamagata K, Iseki K, Nitta K et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008; 12: 1-8.
10. Lysaght M. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13: S37-S40.
11. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
12. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839.
13. Parving H-H, Lewis JB, Ravid M et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69: 2057-2063.
14. Ninomiya T, Perkovic V, de Galan BE et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-1821.
15. Dunstan DW, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
16. White SL, Polkinghorne KR, Cass A et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 2008; 188: 204-208.
17. Whaley-Connell A, Sowers JR, McCullough PA et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009; 53(Suppl 4): S11-S21.
18. Thomas M, Viberti G, Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 2008; 4: 2-3.
19. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008; 25(Suppl 2): 25-29.
21. Gaede P, Lund-Andersen H, Parving H-H et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
22. Patel A and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
23. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
24. Zoungas S, de Galan BE, Ninomiya T et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
25. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.
26. Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878. (Pubitemid 34940826)
27. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
28. Burney B, Kalaitzidis R, Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009; 18: 107-111.